Link to this page
Medical Dictionary for Regulatory Activities Terminology (MedDRA)
| Id | http://purl.bioontology.org/ontology/MEDDRA/20000238
http://purl.bioontology.org/ontology/MEDDRA/20000238
|
|---|---|
| Preferred Name | Sexual dysfunction (SMQ) |
| Definitions |
Sexual dysfunction is defined as any of a group of sexual disorders, signs, or symptoms describing a decrease either of sexual desire or of the psychophysiological changes that usually characterize the sexual response. These encompass sexual desire disorders, sexual arousal disorders, orgasmic disorders, ejaculatory dysfunction, sexual pain disorders, substance/drug-induced sexual dysfunction, and sexual dysfunction due to a general medical condition. Common symptoms include: diminished genital sensation, pleasureless or weak orgasm, anorgasmia, decreased sex drive, inability to achieve erection, premature ejaculation, impaired lubrication, and diminished nipple sensation. Common causes include: altered anatomy or physiology (e.g., pelvic organ prolapse, impotence), nicotine, alcohol, and recreational drug use, hormonal abnormalities or changes, psychiatric disorders including depression, systemic illness, and medications. Medications that can cause sexual dysfunction include: hormonal contraceptives, antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), antiandrogens, 5-alpha reductase inhibitors, opioid analgesics, retinoids. For some medications, sexual side effects may persist even after treatment withdrawal.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | Sexual dysfunction is defined as any of a group of sexual disorders, signs, or symptoms describing a decrease either of sexual desire or of the psychophysiological changes that usually characterize the sexual response. These encompass sexual desire disorders, sexual arousal disorders, orgasmic disorders, ejaculatory dysfunction, sexual pain disorders, substance/drug-induced sexual dysfunction, and sexual dysfunction due to a general medical condition. Common symptoms include: diminished genital sensation, pleasureless or weak orgasm, anorgasmia, decreased sex drive, inability to achieve erection, premature ejaculation, impaired lubrication, and diminished nipple sensation. Common causes include: altered anatomy or physiology (e.g., pelvic organ prolapse, impotence), nicotine, alcohol, and recreational drug use, hormonal abnormalities or changes, psychiatric disorders including depression, systemic illness, and medications. Medications that can cause sexual dysfunction include: hormonal contraceptives, antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), antiandrogens, 5-alpha reductase inhibitors, opioid analgesics, retinoids. For some medications, sexual side effects may persist even after treatment withdrawal. |
|---|---|
| prefLabel | Sexual dysfunction (SMQ)
|
| SMQ STATUS | A
|
| type | |
| tui | T185
|
| notation | 20000238
|
| SMQ LEVEL | 1
|
| Semantic type UMLS property | |
| SMQ ALGO | N
|
| Scope Statement | Sexual dysfunction (SMQ) has been developed by the MedDRA MSSO and an international group of regulatory and industry experts, based on medical judgment. The term list has been derived based on common concepts in class labeling for certain pharmaceutical products with established risks for this condition. The focus of this SMQ is, therefore, on decreased sexual function related to medications rather than other causes. SMQs do not include a temporal assessment so users applying Sexual dysfunction (SMQ) to retrieve potential cases of persistent sexual dysfunction should include case information relative to the discontinuation of medication in their review and analysis.
|
| cui | C5554403
|
| SMQ SOURCE | Sadock BJ, Sadock VA, Ruiz P. Selective serotonin reuptake inhibitors. In: Kaplan & Sadock's Synopsis of Psychiatry, Eleventh Edition, Wolters Kluwer, Philadelphia (2015), p1013. Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5a-reductase inhibitors and isotretinoin: 300 cases. International Journal of Risk and Safety in Medicine (2018), 29:125-134. Bala A, Nguyen HMT, Hellstrom WJG. Post-SSRI Sexual Dysfunction: A literature review. Sexual Medicine Reviews, (2018), 6(1):29-34. Rineke Gordijn, Martina Teichert, Melianthe P.J. Nicolai, Henk W. Elzevier, Henk-Jan Guchelaar, Adverse drug reactions on sexual functioning: a systematic overview, Drug Discovery Today, Volume 24, Issue 3, 2019, Pages 890-897. Trenque, T., Maura, G., Herlem, E. et al. Reports of Sexual Disorders Related to Serotonin Reuptake Inhibitors in the French Pharmacovigilance Database: An Example of Underreporting. Drug Saf 36, 515-519 (2013).
|
| Has member |
See more
See less
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |